The University of Virginia (UVA) was awarded a $742,810 Project Grant from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will support the development of new diagnostic and monitoring tools using hyperpolarized gas magnetic resonance imaging (HGMRI) to detect and manage acute cellular rejection in lung transplant recipients.
Specifically, the project aims to: 1) correlate HGMRI signatures with tissue pathology (the current clinical gold standard), 2) determine HGMRI signature responses before and after rejection treatment, and 3) correlate HGMRI signatures with single-cell RNA sequencing data to understand underlying immunopathology. The project will also assess the persistence of regional acute rejection diagnosis by HGMRI and tissue pathology over a 12-month follow-up period. Successful completion of this research has the potential to advance the field of pulmonary transplant medicine by enabling earlier detection and non-invasive monitoring of rejection in lung transplant patients.
Generated 3/4/25, 7:09 AM